Venetoclax and Hypomethylating Agent Combination in Myeloid Malignancies: Mechanisms of Synergy and Challenges of Resistance
Open Access
- 29 December 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 484
Abstract
There has been a widespread adoption of hypomethylating agents (HMA: 5-Azacytidine (5-Aza)/decitabine) and venetoclax (Ven) for the treatment of acute myeloid leukemia (AML); however, the mechanisms behind the combination’s synergy are poorly understood. Monotherapy often encounters resistance, leading to suboptimal outcomes; however, the combination of HMA and Ven has demonstrated substantial improvements in treatment responses. This study elucidates multiple synergistic pathways contributing to this enhanced therapeutic effect. Key mechanisms include HMA-mediated downregulation of anti-apoptotic proteins, notably MCL-1, and the priming of cells for Ven through the induction of genes encoding pro-apoptotic proteins such as Noxa. Moreover, Ven induces sensitization to HMA, induces overcoming resistance by inhibiting the DHODH enzyme, and disrupts antioxidant pathways (Nrf2) induced by HMA. The combination further disrupts oxidative phosphorylation in leukemia stem cells, amplifying the therapeutic impact. Remarkably, clinical studies have revealed a favorable response, particularly in patients harboring specific mutations, such as IDH1/2, NPM1, CEBPA, or ASXL1. This prompts future studies to explore the nuanced underpinnings of these synergistic mechanisms in AML patients with these molecular signatures.Keywords
This publication has 55 references indexed in Scilit:
- Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cellsAnnals of Hematology, 2012
- Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapiesBlood Cancer Journal, 2012
- Apoptosis in cancer: from pathogenesis to treatmentJournal of Experimental & Clinical Cancer Research, 2011
- The cytoprotective role of the Keap1–Nrf2 pathwayArchives of Toxicology, 2011
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activationBlood, 2009
- The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative StressJournal of Biological Chemistry, 2009
- Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell linesBlood, 2009
- IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell lineOncogene, 1999
- 5-Azacytidine, a new, highly effective cancerostaticCellular and Molecular Life Sciences, 1964